{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:10:02Z","timestamp":1785366602042,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clinthera.2025.07.018","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:18:02Z","timestamp":1755083882000},"page":"875-883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF)"],"prefix":"10.1016","volume":"47","author":[{"given":"Wojciech","family":"Michalak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mads","family":"Faurby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.07.018_bib0001","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J Card Fail"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0002","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.cardfail.2021.12.017","article-title":"Economic issues in heart failure in the United States","volume":"28","author":"Heidenreich","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0003","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0004","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0005","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jchf.2018.08.007","article-title":"Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic\/obese HFpEF","volume":"6","author":"Kitzman","year":"2018","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0006","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCHEARTFAILURE.110.959890","article-title":"Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial","volume":"4","author":"Haass","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/circ.150.suppl_1.4123373","article-title":"Estimating obesity-attributable cardiovascular disease burden in the United States: a Bayesian network analysis","volume":"150","author":"Sheth","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0008","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41366-023-01376-4","article-title":"Real-world costs of obesity-related complications over eight years: a US retrospective cohort study in 28,500 individuals","volume":"47","author":"Pearson-Stuttard","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0009","first-page":"210","article-title":"Complication-specific direct medical costs by body mass index for 13 obesity-related complications: a retrospective database study","volume":"27","author":"Divino","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0010","first-page":"85","article-title":"Early clinical benefit of semaglutide in adults with overweight or obesity and cardiovascular disease: a secondary analysis of the SELECT trial","volume":"18","author":"Plutzky","year":"2025","journal-title":"Obes Fats"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0011","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae666.2792","article-title":"Exploratory mediation analysis of the effect of semaglutide on cardiovascular outcomes in people with overweight or obesity in the SELECT randomised trial","volume":"45","author":"Colhoun","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0012","first-page":"1069","volume":"389","author":"Kosiborod","year":"2023"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0013","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0014","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0015","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0016","unstructured":"Novo Nordisk Inc. Wegovy prescribing information. 2024 Accessed at: https:\/\/www.novo-pi.com\/wegovy.pdf on June 11, 2025."},{"key":"10.1016\/j.clinthera.2025.07.018_bib0018","unstructured":"Komodo Health Solutions. Imputing allowed amounts development and validation of an encounter-level allowed amount imputation model. 2023. Accessed at: https:\/\/knowledge.komodohealth.com\/hubfs\/2023\/Komodo_Imputing_Allowed_Amounts_White_Paper.pdf on February 6, 2025."},{"key":"10.1016\/j.clinthera.2025.07.018_bib0019","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jchf.2014.11.010","article-title":"Assessing the use of international classification of diseases-10th revision codes from the emergency department for the identification of acute heart failure","volume":"3","author":"Frolova","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/pds.4690","article-title":"Diagnostic accuracy of the international classification of diseases, tenth revision, codes of heart failure in an administrative database","volume":"28","author":"Bosco-Levy","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v111.i09","article-title":"How to interpret statistical models using marginaleffects for R and python","volume":"111","author":"Arel-Bundock","year":"2024","journal-title":"J Stat Softw"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0023","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1080\/03610920601126589","article-title":"Inference under heteroskedasticity and leveraged data","volume":"36","author":"Cribari-Neto","year":"2007","journal-title":"Commun Stat - Theory Methods"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0024","first-page":"1","article-title":"Emergency department visits for chest pain and abdominal pain: United States, 1999-2008","volume":"43","author":"Bhuiya","year":"2010","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0025","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13696998.2019.1693384","article-title":"Real-world comparison of hospitalization costs for heart failure in type 2 diabetes mellitus patients with established cardiovascular disease treated with canagliflozin versus other antihyperglycemic agents","volume":"23","author":"Chen","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0026","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jchf.2024.04.003","article-title":"Cause-specific health care costs following hospitalization for heart failure and cost offset with SGLT2i therapy","volume":"12","author":"Kittipibul","year":"2024","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0027","unstructured":"Novo Nordisk Inc. NovoCare\u00ae Pharmacy. Accessed at: https:\/\/www.novocare.com\/obesity\/products\/wegovy\/get-product.html on March 17, 2025."},{"key":"10.1016\/j.clinthera.2025.07.018_bib0028","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13300-024-01678-4","article-title":"Cardiovascular events in adults with type 2 diabetes and ASCVD Initiating once-weekly semaglutide vs DPP-4is in the USA","volume":"16","author":"Inzucchi","year":"2025","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0029","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1146\/annurev.publhealth.20.1.125","article-title":"Methods for analyzing health care utilization and costs","volume":"20","author":"Diehr","year":"1999","journal-title":"Annu Rev Public Health"},{"key":"10.1016\/j.clinthera.2025.07.018_bib0031","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13885","article-title":"Determinants of adherence to obesity medication: a narrative review","author":"Sharma","year":"2025","journal-title":"Obes Rev"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291825002541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T17:58:44Z","timestamp":1759859924000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291825002541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0149291825002541"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.07.018","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Semaglutide 2.4 mg on Healthcare Resource Utilization and Medical Costs in Patients With Heart Failure in the United States (SHINE-HF)","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Novo Nordisk Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}